Michael W Kavanaugh

US Patent:

6716626, Apr 6, 2004

Filed:

Nov 16, 2000

Appl. No.:

09/715805

Inventors:

Nobuyuki Itoh - Kyoto, JP
Michael Kavanaugh - Mill Valley CA

Assignee:

Chiron Corporation - Emeryville CA
Kyoto University - Kyoto

International Classification:

C12N 1585

US Classification:

435325, 4352523, 43525411, 4352542, 4353201, 435 691, 536 231, 536 235, 536 243, 530350

Abstract:

This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.

US Patent:

6797695, Sep 28, 2004

Filed:

Oct 20, 2000

Appl. No.:

09/692945

Inventors:

Nobuyuki Itoh - Kyoto, JP
Michael Kavanaugh - Mill Valley CA

Assignee:

Kyoto University - Kyoto
Chiron Corporation - Emeryville CA

International Classification:

A61K 3818

US Classification:

514 12, 530350

Abstract:

This invention relates to human fibroblast growth factor (hFGF-20), and to variants thereof and to polynucleotides encoding FGF-20. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, to methods of treating neuronal degenerative disease such as Parkinsons disease and to methods of treating disorders of the cochlea including those causing hearing loss. The invention also relates to rat fibroblast growth factor (rFGF-20), and to variants thereof and polynucleotides encoding rFGF-20.

US Patent:

7723297, May 25, 2010

Filed:

Apr 17, 2006

Appl. No.:

11/405241

Inventors:

Nobuyuki Itoh - Sakya, JP
Michael Kavanaugh - Mill Valley CA, US

Assignee:

Kyoto University - Sakyo, Kyoto
Novartis Vaccines and Diagnostics, Inc. - Emeryville CA

International Classification:

A61K 38/18
C07K 14/475

US Classification:

514 12, 530350, 530300

Abstract:

This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.

US Patent:

20040185494, Sep 23, 2004

Filed:

Apr 5, 2004

Appl. No.:

10/818140

Inventors:

Nobuyuki Itoh - Sakyo, JP
Michael Kavanaugh - Mill Valley CA, US

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C07K014/50
C12Q001/68
C07H021/04

US Classification:

435/006000, 435/069100, 435/320100, 435/325000, 530/399000, 536/023500

Abstract:

This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.

US Patent:

20050037457, Feb 17, 2005

Filed:

Feb 3, 2004

Appl. No.:

10/771173

Inventors:

Nobuyuki Itoh - Sakyo, JP
Michael Kavanaugh - Mill Valley CA, US

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C07K014/49

US Classification:

435069100, 435320100, 435325000, 530399000, 536023500

Abstract:

This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.

US Patent:

20060172386, Aug 3, 2006

Filed:

Dec 27, 2005

Appl. No.:

11/318327

Inventors:

Nobuyuki Itoh - Kyoto, JP
Michael Kavanaugh - Mill Valley CA, US

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C07K 14/50
A61K 38/18
C07K 16/22
C12P 21/06
C07H 21/04

US Classification:

435069100, 530350000, 530388240, 435320100, 435325000, 514012000, 536023500

Abstract:

This invention relates to human fibroblast growth factor (hFGF-20), and to variants thereof and to polynucleotides encoding FGF-20. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, to methods of treating neuronal degenerative disease such as Parkinson's disease and to methods of treating disorders of the cochlea including those causing hearing loss. The invention also relates to rat fibroblast growth factor (rFGF-20), and to variants thereof and polynucleotides encoding rFGF-20.

US Patent:

20070128619, Jun 7, 2007

Filed:

May 26, 2006

Appl. No.:

11/441666

Inventors:

Nobuyuki Itoh - Kyoto, JP
Michael Kavanaugh - Mill Valley CA, US

Assignee:

Novartis Vaccines and Diagnostics - Emeryville CA
Kyoto University - Kyoto

International Classification:

C12Q 1/68
G01N 33/53
C07H 21/04
C12P 21/06
C07K 14/50
C07K 16/22

US Classification:

435006000, 435007100, 435069100, 435320100, 435325000, 530399000, 536023500, 530388250

Abstract:

This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-2 1. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.

US Patent:

20090074776, Mar 19, 2009

Filed:

Aug 16, 2007

Appl. No.:

11/894005

Inventors:

Nobuyuki Itoh - Kyoto, JP
Michael Kavanaugh - Mill Valley CA, US

Assignee:

Novartis Vaccines and Diagnostics - Emeryville CA
Kyoto University - Kyoto

International Classification:

A61K 39/395
C07H 21/04
C12N 15/63
C12N 15/00
C12N 5/00
A61K 35/12
C12Q 1/68
A61K 31/7088
C12P 21/06
C07K 14/435
C07K 16/00

US Classification:

4241391, 536 235, 4353201, 435455, 435325, 435 691, 530350, 5303879, 514 44, 424 9321, 435 6

Abstract:

This invention relates to human fibroblast growth factor (hF-GF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.